Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.

ABSTRACT:

Background

There is no currently available treatment for peritoneal metastasis of gastric cancer. This phase II study aimed to evaluate the efficacy and safety of neoadjuvant systemic chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) for the treatment of these patients.

Methods

Neoadjuvant chemotherapy comprised two cycles of HIPEC and four cycles of S-1 plus paclitaxel. HIPEC was administered intraperitoneally with paclitaxel (75 mg/m²). For systemic chemotherapy, paclitaxel was administered intravenously(150 mg/m²) on day 1, and S-1 was administered orally(80 mg/m²/day)on days 1-14 of a 3-week cycle. Another two cycles of HIPEC and four cycles of S-1 plus paclitaxel were administere

SUBMITTER: Yu P 

PROVIDER: S-EPMC7667754 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature